Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Schizophr Res. 2017 Jul 5;193:244–250. doi: 10.1016/j.schres.2017.06.043

Table 1.

Participant Characteristics (N = 35).

Mean Standard Deviation Range
Demographic Characteristics
Age (Years) 18.80 1.73 15 – 22
Gender (M/F) 23/12
Handedness (R/L) 27/1
Race (White/Non-White) 23/11
Parental Education (Years) 15.32 1.97 12 – 18
WRAT Sum IQ 111.31 12.55 87 – 145
Clinical Characteristics
Antipsychotic Medications (Y/N) 8/27
    Chlorpromazine Equivalents (N=8) 119.79 74.79 50 – 250
Positive Symptoms 12.23 5.80 0 – 23
Negative Symptoms 9.17 7.12 0 – 24
Disorganized Symptoms 5.63 4.07 0 – 12
Clinical Insight (SUMD)
Awareness of Mental Disorder 2.14 1.42 0 – 5
Awareness of Medication Effects 1.00 1.39 0 – 4
Awareness of Social Consequences 1.74 1.56 0 – 4
Current Clinical Insight 4.89 3.13 0 – 12

Note, WRAT, Wide Range Achievement Test; SUMD, Scale to Assess Unawareness of Mental Disorder; Symptom severity was assessed with the Structured Interview of Prodromal Syndromes; Chlorpromazine equivalents were computed only for those individuals taking antipsychotics